The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | A success story: IDH inhibitors for AML
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, describes how IDH inhibitors have significantly acute myeloid leukemia (AML) therapy. Dr Perl discusses how these treatments have increased survival rates in AML patients who have previously been unresponsive to therapy and those who were not candidates for intensive chemotherapy. He stresses the importance of personalized, precision medicines.
